Home Drug Study Drug Study:Doxycycline Hyclate(Vibramycin)

Drug Study:Doxycycline Hyclate(Vibramycin)

Drug Study:Doxycycline Hyclate

Generic Name:Doxycycline Hyclate
Brand Name:Adoxa, Apo-Doxy  , Doryx, Doxy, Doxy-Caps, Doxychel, Doxycin  , Doxy-Lemmon, Monodox, Novodoxylin ,SK-Doxycycline, Vibramycin, Vibra-Tabs, Vivox
Classifications:antiinfective; antibiotic; tetracycline
Pregnancy Category:  D
50 mg, 100 mg capsules, tablets;  200 mg injection

Semisynthetic broad- spectrum tetracycline antibiotic derived from oxytetracycline. More completely absorbed with effective blood levels maintained for longer periods and excreted more slowly than most other tetracyclines. Thus it requires smaller and less frequent dosing.

Therapeutic effects
Primarily bacteriostatic in effect. Similar in use to tetracycline (e.g., effective against Chlamydial and Mycoplasmal infections; gonorrhea, syphilis, rickettsia).

Similar to those of tetracycline, e.g., Chlamydial and mycoplasmal infections; gonorrhea, syphilis in penicillin-allergic patients; rickettsial diseases; acute exacerbations of chronic bronchitis.

Unlabeled  uses
Treatment of acute PID, leptospirosis, prophylaxis for rape victims, suppression and chemoprophylaxis of chloroquine-resistant Plasmodium falciparum malaria, short-term prophylaxis and treatment of travelers’ diarrhea caused by enterotoxigenic strains of Escherichia coli. Intrapleural administration for malignant pleural effusions.

Route & dosage 

adult: PO/IV  100 mg q12 h on day 1, then 100 mg/d as single dose (max: 100 mg q12 h)
child: PO/IV  8 y, 4.4 mg/kg in 1–2 doses on day 1, then 2.2–4.4 mg/kg/d in 1–2 divided doses

adult: PO  200 mg immediately, followed by 100 mg h.s., then 100 mg b.i.d. for 3 d

Primary and Secondary Syphilis
adult:  PO  300 mg/d in divided doses for at least 10 d

Travelers’ Diarrhea
adult: PO  100 mg/d during risk period (up to 2 wk) beginning day 1 of travel

adult: PO  100 mg q 12 h on day 1, then 100 mg q.d.
child: PO  >8y and >45 kg 100 mg q 12 h on day 1, then 100 mg q.d.; >8 y and <45 kg, 2.2 mg/kg q 12 h day 1 then 2.2 mg/kg/d q.d.



 Check expiration date. Degradation products of tetracycline are toxic to the kidneys.

Give with food or a full glass milk to minimize nausea without significantly affecting bioavailability of drug (UNLIKE MOST TETRACYCLINES).

 Consult physician about ordering the oral suspension for patients who are bedridden or have difficulty swallowing.


PREPARE  intermittentcontinuous: Reconstitute by adding 10 mL sterile water for injection, or D5W, NS, LR, D5/LR or other diluent recommended by manufacturer, to each 100 mg of drug. • Further dilute with 100–1000 mL (per 100 mg of drug) of compatible infusion solution to produce concentrations ranging from 0.1 to 1 mg/mL.

ADMINISTER  intermittentcontinuous: IV infusion rate will usually be prescribed by physician. • Duration of infusion varies with dose but is usually 1–4 h. • Recommended minimum infusion time for 100 mg of 0.5 mg/mL solution is 1 h. Infusion should be completed within 12 h of dilution. • When diluted with LR or D5/LR, infusion must be completed within 6 h to ensure adequate stability. • Protect all solutions from direct sunlight during infusion.

  • Store oral and parenteral forms (prior to reconstitution) in tightly covered,–resistant light containers at 15°–30° C (59°–86° F) unless otherwise directed. • Refrigerate reconstituted solutions for up to 72 h. After this time, infusion must be completed within 12 h.

Adverse effects

 SpecSenses: Interference with color vision.
 GI: Anorexia, nausea, vomiting, diarrhea, enterocolitis; esophageal irritation (oral capsule and tablet).
 Skin: Rashes, photosensitivity reaction.
 other: Thrombophlebitis (IV use), superinfections.

Nursing implications 

Assessment & Drug Effects

  • Report sudden onset of painful or difficult swallowing promptly to physician. Doxycycline (capsule and tablet forms) is associated with a comparatively high incidence of esophagitis,especially in patients >40 y.
  • Report evidence of super infections

Patient & Family Education

  •  Take capsule or tablet forms with a full glass (240 mL) of water to ensure passage into stomach and prevent esophageal ulceration. Avoid taking capsule or tablet within 1 h of lying down or retiring.
  •  Avoid exposure to direct sunlight and ultraviolet light during and for 4 or 5 d after therapy is terminated to reduce risk of phototoxic reaction. Phototoxic reaction appears like an exaggerated sunburn. Sunscreens provide little protection.
  • Do not breast feed while taking this drug.
This community comprises professional nurses who possess exceptional literary skills. They come together to share their expertise in theoretical and clinical knowledge, nursing tips, facts, statistics, healthcare information, news, disease data, care plans, drugs, and all aspects encompassed by the field of nursing. The information presented here is provided by individual authors and is expressed with courtesy. It is important to note that the views expressed on various topics may not necessarily represent those of the entire community. The articles submitted to this platform are original, meticulously checked for minor typographical errors, and formatted to ensure compatibility with the site. The site's primary goal is to consistently enhance and disseminate healthcare information that is pertinent to the ever-evolving world we live in today.


Please enter your comment!
Please enter your name here